The Max Vincze Foundation funds innovative research to discover therapies for NUT carcinoma and other rare young adult cancers.
At the Max Vincze Foundation, our mission is to make targeted investments in research that focus on groundbreaking discoveries, specifically targeting rare cancers found in adolescents and young adults such as NUT carcinoma.
ABOUT US
The Max Vincze Foundation was founded by Craig, Suzanne and Ben Vincze in honor of their late son and brother Max, who tragically lost his battle with NUT Carcinoma, an untreatable and lethal form of cancer that predominantly afflicts adolescents and young adults.
The Vincze family recognized the urgent need to address the lack of viable treatment options for adolescents and young adults facing this aggressive and deadly cancer. With unwavering determination, they have transformed their personal tragedy into a mission to empower research and find new treatments.
OUR CHARITABLE PURPOSE
With your support, we empower research labs to pursue the bold, innovative science needed to discover new treatments and cures for rare cancers like NUT carcinoma—breakthroughs that often go unfunded by traditional sources.
Private funding gives researchers the freedom to challenge conventional thinking and explore unconventional approaches that are essential for progress against rare diseases.
OUR INITIATIVES
After nearly a year of due diligence, the Max Vincze Foundation committed to making its very first gift to the Dana-Farber Cancer Institute in Boston, MA to strengthen efforts to find a treatment for NUT carcinoma. Dana-Farber Cancer Institute established and maintains the extremely important NUT Carcinoma International Registry and are developing new, promising treatments and ushering them into clinical trials as quickly as possible.
Thanks to our generous donors, the Max Vincze Foundation was able to complete the last installment of a $100,000 donation to the Dana-Farber Cancer Institute in July of 2023.
Left to right: Suzanne Vincze, Ben Vincze (Max’s brother), Taylor Durall, Craig Vincze, Dora Huang and Dr. Chris French, M.D.